close

Register today to unlock Valuecruncher and get unlimited access

  • Get unlimited access to all compartors and data
  • Save and share valuations as well as comment on others
  • Alter and save your favourite comparator companies

Already registered? Please login now

Comparison Analysis  

What's this?
Dollar30Point34
Implied share price

Sell Overvalued by 61.2%

5% margin of safety What's this?

EV / Revenue
Use Average
ABII
Abraxis Bioscience, Inc.
GILD
Gilead Sciences, Inc.
Change
AMGN
Amgen, Inc.
Change
NVO
Novo Nordisk A/S (ADR)
Change
SNY
Sanofi SA (ADR)
Change
2.85 8.25 3.59 5.02 1.0 1.67
All amounts in millions
from last financial year
         
Implied Share Price $30.34 $64.33 $82.22 $131.05 $70.81
Market Cap 3,166 109,622 108,611 106,224 100,733
Net Debt -203 7,450 47 -19,392 7,295
Enterprise Value (EV) 2,963 117,072 108,657 108,147 58,232
Revenue 359 32,639 21,662 107,927 34,861
Balance Sheet          
Total Assets 1,068 51,716 71,449 91,799 102,321
Total Liabilities 225 33,182 43,366 44,830 44,272
Shareholders Equity 842 18,534 28,083 46,969 58,049.0

Where are the EBIT and EBITDA figures?

Certain companies and those in specific industries (for example insurance) do not report financial results at the EBIT or EBITDA line. For these companies where Valuecruncher does not have EBIT or EBITDA numbers we exclude the valuation metrics driven by these figures. Valuecruncher makes our other valuation metrics available for these companies.

To learn more about comparison analysis, please read our guide to comparison analysis

Comments

No comments yet. Login to comment.